Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 249

Results For "aging"

2596 News Found

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
Biotech | August 10, 2021

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings

A veteran in cell therapy and oncology commercialisation


Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Digitisation | August 10, 2021

Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests

Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection


India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul
Healthcare | August 09, 2021

India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul

By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas


Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US


TAKE divests stake in Navitas Life Sciences to HIG
Biotech | August 08, 2021

TAKE divests stake in Navitas Life Sciences to HIG

The transaction is expected to close in the Q4FY22


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr
News | August 07, 2021

Bafna Pharma posts Q1FY 21-22 net at Rs. 2.08 Cr

This robust growth has come despite the raging pandemic for most part of the quarter


Stelis Biopharma appoints Mark W. Womack as CEO
People | August 07, 2021

Stelis Biopharma appoints Mark W. Womack as CEO

He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations


Strides to acquire US manufacturing facility of Endo for $24 mn
News | August 06, 2021

Strides to acquire US manufacturing facility of Endo for $24 mn

The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.


Mark W. Womack is the new CEO of Stelis Biopharma
Biotech | August 06, 2021

Mark W. Womack is the new CEO of Stelis Biopharma

He will be stationed at the company HQ in Bengaluru, India